KFDA unveils drug re-evaluation results
Published: 2009-03-30 06:59:00
Updated: 2009-03-30 06:59:00
The Korea Food and Drug Administration announced on March 26 that it will retract its approval for problematic 14 generic drugs in terms of bioequivalence, banning pharmaceutical companies from manufacturing and selling them.
These drugs included simvastatin generics manufactured by Kwangdong ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
